glp 1 heart attack Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of tirzepatide | Cardiovascular Diabetology Cardiovascular benefits of glucagon-like peptide-1

Serine and one-carbon metabolism in cancer

Download Your Complimentary Copy of the 2026 Agenda The 3rd GLP-1 Based Therapeutics Summit was the definitive industry platform focussed on accelerating the next era of GLP-1 therapeutics, driving clinical and commercial advantage across indications

This complexity is further heightened by differences in adiponectin production between visceral and subcutaneous fat, notably with obesity-associated declines in adiponectin from subcutaneous sources [33]

time 56 (n) 55 (n) Tau 2 = 0.00, I 2 = 0.0%, p = 0.043 Early treatment 21% 0.79 [0.63-0.99] 0/285 1/131 21% lower risk de Alencar (DB RCT) -10% 1.10 [0.37-3.23] hosp